人类氨甲酰化蛋白质组描述鉴定出氨甲酰化α2-巨球蛋白和血红素结合蛋白作为早期类风湿关节炎的两种新型自身抗原
研究对类风湿关节炎患者血清和滑液进行质谱分析以描绘人类氨甲酰化蛋白质组,鉴定出11种新型氨甲酰化蛋白并选择5种建立ELISA。在189例早期RA患者中,抗氨甲酰化血红素结合蛋白和抗氨甲酰化α2-巨球蛋白抗体诊断价值与已建立的氨甲酰化胎牛血清ELISA相当,联合ACPA和RF可识别89%的早期RA患者。
要点
- 质谱鉴定出11种新型氨甲酰化蛋白,5种用于建立抗CarPAs检测ELISA。
- 抗CaHPX和抗CaA2M诊断价值与氨甲酰化胎牛血清ELISA相当。
- 联合ACPA和RF可识别89%的早期RA患者,各抗原可识别不同血清阴性RA亚群。
核心结论
- 采用滑液和血清联合蛋白质组学方法在体内检测到新型氨甲酰化自身抗原,抗CaHPX和抗CaA2M是有前景的临床生物标志物,尤其在血清阴性RA中。
研究设计与样本
- 对RA患者滑液和血清进行质谱分析,选择两种样本中均存在的氨甲酰化蛋白作为候选自身抗原建立ELISA,并在189例早期RA患者队列中检测特异性抗CarPAs阳性。
主要发现
- 鉴定出11种新型氨甲酰化蛋白,选择其中5种作为检测抗CarPAs的潜在自身抗原。
- 抗CaHPX和抗CaA2M抗体诊断价值与已建立的氨甲酰化胎牛血清ELISA相当。
- 189例早期RA患者中,新生物标志物联合ACPA和RF识别出89%的早期RA患者。
- 所检测的生物标志物之间相关性很小,每种抗原可识别不同的血清阴性RA患者亚群。
- 抗CaA2M阳性与更高的疾病残疾相关,显示临床潜力。
关键数值与推荐
- 抗CaHPX和抗CaA2M诊断价值与氨甲酰化胎牛血清ELISA相当。
- 新生物标志物联合ACPA和RF识别89%的早期RA患者(189例队列)。
- 抗CaA2M阳性与更高疾病残疾相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Anti-carbamylated protein antibodies (anti-CarPAs) are present in RA sera and have been associated with erosive disease. The exact targets of anti-CarPAs in vivo are currently not well known; we used a proteomic approach on serum and SF of RA patients to assess the human carbamylome and to identify carbamylated autoantigens as potential biomarkers in early RA. METHODS: Mass spectrometry was performed on SF and serum from RA patients. Carbamylated proteins present in both sample types were selected as candidate autoantigens for the establishment of ELISAs. A cohort of early RA patients was tested for positivity for specific anti-CarPAs. RESULTS: Eleven novel carbamylated proteins were identified, and five were selected as potential autoantigens for detection of anti-CarPAs. Among them, antibodies against carbamylated hemopexin (anti-CaHPX) and alpha-2-macroglobulin (anti-CaA2M) showed comparable diagnostic value to the established carbamylated foetal calf serum-based ELISA. A cohort of 189 early RA patients was studied. The combination of these new biomarkers with anti-citrullinated protein antibodies and RF identified 89% of early RA patients in our cohort. There was little correlation between the tested biomarkers, and each one of the tested antigens could identify a different subset of seronegative RA patients. Anti-CaA2M positivity showed clinical potential, being associated with higher disease disability. CONCLUSION: We highlight the detection of novel carbamylated autoantigens in vivo using a combined proteomics approach in the SF and serum of RA patients. Anti-CaHPX and anti-CaA2M are promising clinical biomarkers, especially in seronegative RA.
引用
- Sidiras P, Lechanteur J, Imbault V, et al. Human carbamylome description identifies carbamylated α2-macroglobulin and hemopexin as two novel autoantigens in early rheumatoid arthritis. Rheumatology (Oxford). 2022. PMID: 34788409. doi:10.1093/rheumatology/keab838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。